INCYTE CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INCYTE CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.39B | Feb 7, 2023 |
| FY2022 | Dec 31, 2021 | $2.99B | Feb 7, 2023 |
| FY2022 | Dec 31, 2020 | $2.67B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $2.16B | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $1.88B | Feb 9, 2021 |
| FY2017 | Dec 31, 2017 | $444.16M | Feb 15, 2018 |
| FY2017 | Sep 30, 2017 | $381.53M | Feb 15, 2018 |
| FY2017 | Jun 30, 2017 | $326.44M | Feb 15, 2018 |
| FY2017 | Mar 31, 2017 | $384.08M | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $326.50M | Feb 15, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.14B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $4.24B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $3.70B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $3.39B | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $2.99B | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $789.51M | Feb 9, 2021 |
| FY2020 | Sep 30, 2020 | $620.64M | Feb 9, 2021 |
| FY2020 | Jun 30, 2020 | $688.04M | Feb 9, 2021 |
| FY2020 | Mar 31, 2020 | $568.51M | Feb 9, 2021 |
| FY2020 | Dec 31, 2019 | $579.39M | Feb 9, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $32.62M | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $597.60M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $340.66M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $948.58M | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $149.85M | Feb 9, 2021 |
| FY2020 | Sep 30, 2020 | ($15.20M) | Feb 9, 2021 |
| FY2020 | Jun 30, 2020 | $290.30M | Feb 9, 2021 |
| FY2020 | Mar 31, 2020 | ($720.64M) | Feb 9, 2021 |
| FY2020 | Dec 31, 2019 | $111.01M | Feb 9, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $61.37M | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $620.53M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $579.44M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $585.78M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | ($263.68M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $402.01M | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $129.22M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | ($243.39M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $145.00M | Feb 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.61B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $1.63B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $1.59B | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $1.46B | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $2.22B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $1.15B | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $1.20B | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $1.33B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $581.86M | Feb 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.24B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $1.16B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $1.00B | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $739.56M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $516.92M | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $468.71M | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $434.41M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $366.29M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $303.25M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.41B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $335.34M | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $496.49M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $969.94M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $749.49M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | ($124.60M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $710.66M | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $336.23M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | ($92.99M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $304.76M | Feb 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2024 | $48.70M | Feb 10, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.96B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $5.44B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $6.78B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $5.84B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $4.93B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $3.56B | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $3.43B | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.65B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.30B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.64B | Feb 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.00B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.59B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $1.47B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $1.16B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $949.65M | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $828.34M | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $719.80M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $671.95M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.22B | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.17B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.45B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $5.19B | Feb 10, 2026 |
| FY2025 | Dec 31, 2022 | $4.37B | Feb 10, 2026 |
| FY2024 | Dec 31, 2021 | $3.77B | Feb 10, 2025 |
| FY2023 | Dec 31, 2020 | $2.61B | Feb 13, 2024 |
| FY2022 | Dec 31, 2019 | $2.60B | Feb 7, 2023 |
| FY2021 | Dec 31, 2018 | $1.93B | Feb 8, 2022 |
| FY2020 | Dec 31, 2017 | $1.63B | Feb 9, 2021 |
| FY2019 | Dec 31, 2016 | $419.47M | Feb 13, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.00M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $155.59M | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $155.59M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $155.59M | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $155.59M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $155.59M | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $155.59M | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $155.59M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $155.59M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $155.59M | Feb 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $213.77M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | ($1.07B) | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $160.39M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | ($437.21M) | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | ($777.87M) | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | ($1.73B) | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | ($1.43B) | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | ($1.88B) | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | ($1.99B) | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | ($1.67B) | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.10B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.69B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.21B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.95B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.06B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $1.51B | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $1.83B | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.16B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $899.51M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $652.34M | Feb 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $19.09B | Feb 14, 2019 |
| FY2017 | Dec 31, 2017 | $26.80M | Feb 15, 2018 |
| FY2016 | Dec 31, 2016 | $749.80M | Feb 14, 2017 |
| FY2015 | Dec 31, 2015 | $749.80M | Feb 12, 2016 |
| FY2014 | Dec 31, 2014 | $840.90M | Feb 17, 2015 |
| FY2013 | Dec 31, 2013 | $846.60M | Feb 21, 2014 |
| FY2012 | Dec 31, 2012 | $410.00M | Feb 21, 2013 |
| FY2011 | Dec 31, 2011 | $420.00M | Feb 22, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 9, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 9, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 9, 2021 |
| FY2020 | Mar 31, 2020 | (3) | Feb 9, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 9, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 9, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 9, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 9, 2021 |
| FY2020 | Mar 31, 2020 | (3) | Feb 9, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 9, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 198.46M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | 193.43M | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | 224.29M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | 222.75M | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | 221.08M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | 219.49M | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | 216.18M | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | 213.27M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 211.26M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | 188.85M | Feb 15, 2018 |